Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib for Chemoprevention of Head and Neck Cancer
NCT01414426Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jan 2012
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in Lip and oral cavity squamous cell carcinoma (OSCC), sponsored by University of Chicago. Started Jan 2012; status: completed.
02
Drugs
vandetanib
03
Conditions
Lip and oral cavity squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT01414426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01414426.